REG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Final Results

HUTCHMED (China)Announcement

06/02/2026 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260206:nRSF9522Ra&default-theme=true

RNS Number : 9522R  Hutchmed (China) Limited  06 February 2026

HUTCHMED to Announce 2025 Final Results

 

Hong Kong, Shanghai & Florham Park, NJ - Friday, February 6, 2026:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern
Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong
Time (HKT).

 

HUTCHMED management will host two webcast presentations for analysts and
investors to discuss the final results, followed by Q&A sessions. The
English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST
(1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at
8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on
Thursday, March 5, 2026).

 

Both webcasts will be available live via the website of the Company at
www.hutch-med.com/event/ (https://www.hutch-med.com/event/) . The presentation
will be available to download shortly before the webcast begins. A replay will
also be available on the website shortly after the event.

 

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
     Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGGZNKNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved